Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky increased its stake in shares of Exact Sciences Co. (NASDAQ:EXASGet Rating) by 40.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 66,035 shares of the medical research company’s stock after purchasing an additional 19,129 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Exact Sciences were worth $4,617,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of EXAS. Dimensional Fund Advisors LP grew its stake in Exact Sciences by 7.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 395,186 shares of the medical research company’s stock worth $30,756,000 after purchasing an additional 26,058 shares in the last quarter. Rhumbline Advisers grew its stake in Exact Sciences by 2.3% during the 4th quarter. Rhumbline Advisers now owns 167,247 shares of the medical research company’s stock worth $13,017,000 after purchasing an additional 3,786 shares in the last quarter. abrdn plc grew its stake in Exact Sciences by 2.0% during the 4th quarter. abrdn plc now owns 17,934 shares of the medical research company’s stock worth $1,396,000 after purchasing an additional 356 shares in the last quarter. Geode Capital Management LLC grew its stake in Exact Sciences by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 2,171,966 shares of the medical research company’s stock worth $168,782,000 after purchasing an additional 76,790 shares in the last quarter. Finally, KRS Capital Management LLC acquired a new position in Exact Sciences during the 4th quarter worth $78,000. 90.95% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Piper Sandler decreased their price target on Exact Sciences from $50.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, August 17th. Benchmark decreased their price target on Exact Sciences to $54.00 in a report on Tuesday, August 9th. Cowen decreased their price target on Exact Sciences from $83.00 to $67.00 and set an “outperform” rating for the company in a report on Wednesday, August 3rd. Credit Suisse Group assumed coverage on Exact Sciences in a report on Wednesday, August 24th. They set an “outperform” rating and a $55.00 price target for the company. Finally, StockNews.com raised Exact Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 26th. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Exact Sciences presently has an average rating of “Moderate Buy” and an average price target of $69.14.

Exact Sciences Stock Down 4.0 %

EXAS opened at $39.25 on Monday. The business has a 50 day moving average price of $42.18 and a two-hundred day moving average price of $51.07. The company has a quick ratio of 2.23, a current ratio of 2.48 and a debt-to-equity ratio of 0.70. The company has a market cap of $6.95 billion, a PE ratio of -9.28 and a beta of 1.37. Exact Sciences Co. has a 52 week low of $34.16 and a 52 week high of $108.99.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the sale, the director now directly owns 60,318 shares of the company’s stock, valued at approximately $2,722,754.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the sale, the director now directly owns 60,318 shares of the company’s stock, valued at approximately $2,722,754.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Katherine S. Zanotti sold 1,086 shares of the firm’s stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $40.13, for a total value of $43,581.18. Following the completion of the sale, the director now directly owns 60,318 shares of the company’s stock, valued at $2,420,561.34. The disclosure for this sale can be found here. Insiders sold a total of 5,701 shares of company stock valued at $251,872 in the last ninety days. Insiders own 1.30% of the company’s stock.

Exact Sciences Profile

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Recommended Stories

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASGet Rating).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.